In 2023, a paper published in Cell Metabolism described a synthetic compound that made sedentary mice run nearly 50% further — without any additional training. The compound was SLU-PP-332, a pan-agonist of the estrogen-related receptor (ERR) family. Since that publication, the research community has taken serious notice. This article breaks down what SLU-PP-332 is, what the current science shows, and why it has become one of the most discussed exercise-mimetic compounds in preclinical research.
What Is SLU-PP-332?
SLU-PP-332 is a small-molecule agonist that simultaneously activates all three estrogen-related receptors: ERRα (alpha), ERRβ (beta), and ERRγ (gamma). These receptors are nuclear transcription factors — they don’t respond to estrogen directly, but instead regulate the expression of genes involved in mitochondrial biogenesis, oxidative metabolism, and energy homeostasis. The compound was developed by researchers at the Scripps Research Institute, primarily in the laboratory of Dr. Thomas Burris, whose group has published extensively on ERR biology.
Unlike PPAR-delta agonists such as GW-501516 (Cardarine), which target fat-burning pathways through a different receptor class, SLU-PP-332 works upstream in the mitochondrial production pathway. In simple terms: ERRs are the master switches that tell cells to build more mitochondria. More mitochondria means more capacity to burn fuel, produce ATP, and sustain aerobic output. Activating all three ERR subtypes simultaneously is what makes SLU-PP-332 a “pan-agonist” — and what appears to give it a uniquely potent effect profile in animal models.
Research Overview
The landmark study on SLU-PP-332 was published in Cell Metabolism in 2023 by Zuercher et al. at Scripps Research. In the study, mice treated with SLU-PP-332 showed dramatically increased running endurance — covering 70% more distance on a treadmill test compared to untreated controls. Muscle biopsies from treated animals revealed elevated expression of genes associated with slow-twitch (Type I) muscle fiber development and enhanced mitochondrial content, mirroring the molecular signature of aerobic exercise training.
Additional preclinical findings have pointed to potential metabolic benefits beyond endurance. Treated animals showed improved fat oxidation and markers consistent with protection against obesity-related metabolic dysfunction. The compound appeared to shift muscle fiber composition toward the oxidative phenotype — the same adaptation elite endurance athletes develop over years of training — in a matter of weeks.
Relevant literature: PubMed search: SLU-PP-332 ERR agonist | Google Scholar: SLU-PP-332
Community Discussion
The research community and biohacker forums have been actively discussing SLU-PP-332 since the Scripps paper gained mainstream attention. Discussions on Reddit have compared it to Cardarine, debated optimal stacking strategies, and analyzed the limited self-report data emerging from early adopters. A good starting point for community perspectives: r/Peptides — SLU-PP-332 discussion threads.
Potential Benefits Studied
- Increased aerobic endurance — preclinical data showed ~70% improvement in treadmill distance in untrained mice
- Mitochondrial biogenesis — elevated expression of PGC-1α and downstream mitochondrial gene networks in skeletal muscle
- Type I muscle fiber upregulation — shift toward slow-twitch oxidative fibers, the hallmark of aerobic conditioning
- Enhanced fat oxidation — preferential mobilization of lipids as a fuel source during sustained activity
- Metabolic protection — early data suggests potential utility in obesity and metabolic syndrome models
- Cardiac muscle effects — ERRγ activation appears particularly relevant in cardiac tissue, with potential implications for heart failure research
Dosage & Administration
All dosing information below is derived from preclinical animal studies and is presented strictly for research reference. SLU-PP-332 is not approved for human use. In the Scripps mouse studies, the compound was administered via intraperitoneal injection at doses in the range of 100 mg/kg, though the dose-response relationship across species and administration routes requires further investigation. The 500mcg formulation available for research allows investigators to explore low-dose protocols and pharmacokinetic profiling. Oral bioavailability studies remain limited, and researchers working with this compound should review the primary literature carefully before designing any administration protocol.
Where to Find It
SLU-PP-332 500mcg is available for research purposes at Combat Research. You can find it here: SLU-PP-332 500mcg — combatresearch.is. Combat Research also carries higher-dose formulations (10mg and 20mg) as well as combination products pairing SLU-PP-332 with Cardarine and 5-Amino-1MQ for researchers interested in synergistic endurance and metabolic protocols.
Conclusion
SLU-PP-332 represents one of the most mechanistically interesting compounds to emerge from academic exercise biology in recent years. Its ability to simultaneously activate all three ERR subtypes places it in a unique category — distinct from PPAR agonists, GH secretagogues, or traditional SARMs. The preclinical endurance data is striking, and the molecular basis for those results is well-characterized. That said, human data is nonexistent, long-term safety profiles have not been established, and the translation from mouse models to human physiology remains an open question. Researchers approaching this compound should do so with rigorous methodology and a thorough reading of the primary literature.
Disclaimer
This article is intended for educational and research purposes only. SLU-PP-332 is not approved by the FDA for human use and is not intended to diagnose, treat, cure, or prevent any disease or condition. All information presented here is derived from preclinical research. Combat Research sells this compound for laboratory and research use only. Consult a qualified healthcare professional before considering any experimental compound.
